Erciyes Demet, Bora Ejder Saylav, Tekindal Mustafa Agah, Erbaş Oytun
Department of Cardiology, Faculty of Medicine, Demiroğlu Bilim University, 34394 Istanbul, Türkiye.
Department of Emergency Medicine, Faculty of Medicine, Izmir Katip Çelebi University, 35620 Izmir, Türkiye.
J Clin Med. 2024 Aug 8;13(16):4637. doi: 10.3390/jcm13164637.
: Diabetic cardiomyopathy (DCM) poses a significant risk for heart failure in individuals with diabetes, yet its underlying mechanisms remain incompletely understood. Elevated blood sugar levels initiate harmful processes, including apoptosis, collagen accumulation, and fibrosis in the heart. Vinpocetine, a derivative of L., has demonstrated diverse pharmacological effects, including vasodilation, anti-inflammatory properties, and enhanced cellular metabolism. This study aims to investigate Vinpocetine's protective and remodeling effects in diabetic cardiomyopathy by evaluating biochemical and histopathological parameters. : Twenty-one adult male Wistar rats were induced with diabetes using streptozocin and divided into Diabetes and Diabetes + Vinpocetine groups. Histopathological analyses, TGF-β1 immunoexpression, and measurements of plasma markers (TGF-β, pro-BNP, Troponin T) were performed. Biochemical analyses included HIF-1 alpha and neuregulin-1β quantification and evaluation of lipid peroxidation. : Vinpocetine significantly reduced cardiac muscle thickness, TGF-β1 expression, and plasma in diabetic rats. HIF-1 alpha and neuregulin-1β levels increased with Vinpocetine treatment. Histopathological observations confirmed reduced fibrosis and structural abnormalities in Vinpocetine-treated hearts. : This study provides comprehensive evidence supporting the protective effects of Vinpocetine against diabetic cardiomyopathy. Vinpocetine treatment improved cardiac morphology, immunohistochemistry, and modulation of biochemical markers, suggesting its potential as a therapeutic intervention to attenuate the negative impact of diabetes on heart function.
糖尿病性心肌病（DCM）给糖尿病患者带来了显著的心力衰竭风险，但其潜在机制仍未完全明确。血糖水平升高会引发心脏中的有害过程，包括细胞凋亡、胶原蛋白积累和纤维化。长春西汀是夹竹桃科植物的一种衍生物，已显示出多种药理作用，包括血管舒张、抗炎特性以及增强细胞代谢。本研究旨在通过评估生化和组织病理学参数，研究长春西汀对糖尿病性心肌病的保护和重塑作用。：使用链脲佐菌素诱导21只成年雄性Wistar大鼠患糖尿病，并将其分为糖尿病组和糖尿病 + 长春西汀组。进行了组织病理学分析、TGF-β1免疫表达以及血浆标志物（TGF-β、脑钠肽前体、肌钙蛋白T）的测量。生化分析包括HIF-1α和神经调节蛋白-1β的定量以及脂质过氧化的评估。：长春西汀显著降低了糖尿病大鼠的心肌厚度、TGF-β1表达和血浆水平。长春西汀治疗后HIF-1α和神经调节蛋白-1β水平升高。组织病理学观察证实长春西汀治疗的心脏纤维化和结构异常减少。：本研究提供了全面的证据支持长春西汀对糖尿病性心肌病的保护作用。长春西汀治疗改善了心脏形态、免疫组织化学以及生化标志物的调节，表明其作为一种治疗干预措施，有可能减轻糖尿病对心脏功能的负面影响。
